Rein Therapeutics Changes Auditors Amidst Reporting Disagreement
Ticker: RNTX · Form: 8-K · Filed: Apr 17, 2025 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Rein Therapeutics, Inc. (RNTX) |
| Form Type | 8-K |
| Filed Date | Apr 17, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, accounting
TL;DR
Rein Therapeutics swapped PwC for EY, citing disagreements with PwC's accounting advice.
AI Summary
Rein Therapeutics, Inc. announced on April 16, 2025, a change in its certifying accountant. The company has dismissed PricewaterhouseCoopers LLP and engaged Ernst & Young LLP as its new independent registered public accounting firm, effective immediately. This change follows a disagreement with PricewaterhouseCoopers regarding the company's financial reporting.
Why It Matters
A change in auditors, especially one involving a disagreement, can signal potential issues with a company's financial reporting or internal controls, warranting closer investor scrutiny.
Risk Assessment
Risk Level: medium — A change in auditors, particularly when linked to disagreements over financial reporting, introduces uncertainty and potential risks related to financial statement accuracy.
Key Players & Entities
- Rein Therapeutics, Inc. (company) — Registrant
- PricewaterhouseCoopers LLP (company) — Former Certifying Accountant
- Ernst & Young LLP (company) — New Certifying Accountant
- April 16, 2025 (date) — Date of Earliest Event Reported
FAQ
When was the change in certifying accountant effective?
The change in certifying accountant was effective immediately as of April 16, 2025.
What was the reason for dismissing PricewaterhouseCoopers LLP?
The filing states that the dismissal of PricewaterhouseCoopers LLP was due to a disagreement with them on any matter of accounting principles or financial statement disclosure.
Who is Rein Therapeutics, Inc.'s new independent registered public accounting firm?
Rein Therapeutics, Inc. has engaged Ernst & Young LLP as its new independent registered public accounting firm.
Did PricewaterhouseCoopers LLP audit any financial statements for Rein Therapeutics, Inc.?
Yes, PricewaterhouseCoopers LLP audited the financial statements of Rein Therapeutics, Inc. for the fiscal year ended December 31, 2024.
Has Rein Therapeutics, Inc. provided PricewaterhouseCoopers LLP with a copy of this filing?
Yes, Rein Therapeutics, Inc. has provided PricewaterhouseCoopers LLP with a copy of this filing and has advised them that it will furnish them with a copy of the correspondence from Ernst & Young LLP.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 17, 2025 regarding Rein Therapeutics, Inc. (RNTX).